2013 EACPT Geneva Congress Symposia: Clinical trial regulation, control and benefits

-->

Abstract submission is now open for the next EACPT Congress, to be held in Geneva 28-31 August 2013. The congress includes symposia, keynote lectures and peer-reviewed oral and poster communications

Symposium on clinical trial regulation, control and benefits

In July 2012, the European Commission adopted a proposal for a Regulation on Clinical Trials. This is now under discussion by the European Parliament and the Council. Input from affected stakeholders is deemed also critical to end up in an optimised legislative framework for clinical trials in Europe. During next year the discussion process should be reaching its end. This session will be a unique opportunity to share and discuss first hand opinions from two key stakeholders intervening in clinical trials, regulatory bodies and academia, and discuss together benefits and risks associated to the legislative proposal.

2013 EACPT Congress

Over 900 participants are expected to attend including health professionals, scientists, policy makers, biotechnology and pharmaceutical professionals, and others with an interest in basic and clinical pharmacology, pharmacotherapy, drug discovery and development, regulatory affairs and related areas.

See here for more on key themes of the Congress.

EACPT Geneva 2013 Congress website  www.eacpt2013.org 

2013 EACPT Congress Symposia: Methodological issues in clinical trials with CNS drugs

Abstract submission is now open for the next EACPT Congress, to be held in Geneva 28-31 August 2013. The congress includes symposia, keynote lectures and peer-reviewed oral and poster communications

Symposium on Methodological issues in clinical trials with CNS drugs

Clinical trials provide the basis for the acquisition of the critical information that physicians need for rational prescribing. Therefore, clinical trials should be designed and conducted utilizing clinically meaningful procedures and endpoints and potential bias should be minimized.

Methodological issues in clinical trials of central nervous system (CNS) drugs include aspects related to study design, procedures of randomization, inclusion and exclusion criteria, treatment outcome measures, sample size, statistical power and ethical considerations.

In this respect, the use of placebo arms in randomized controlled trials remains a very controversial problem when evaluating the efficacy and safety of medications used to treat neurological or psychiatric disorders. This symposium focuses mainly on the shortcomings of clinical trials in epilepsy, neuropathic pain and schizophrenia.  

Over 900 participants are expected to attend including health professionals, scientists, policy makers, biotechnology and pharmaceutical professionals and others with an interest in basic and clinical pharmacology, pharmacotherapy, drug discovery and development, regulatory affairs and related areas.

See here for more on key themes of the Congress.

EACPT Geneva 2013 Congress website  www.eacpt2013.org